News Headlines Article

FDA approves Cepheid test for hospital-acquired infections
San Jose Business Journal

Cepheid said Wednesday it received clearance from the U.S. Food & Drug Administration to market Xpert vanA, a test for vanA, the antimicrobial resistance gene most commonly associated with one of the more serious healthcare-associated infections. Sunnyvale-based Cepheid (NASDAQ:CPHD) said the U.S. Centers for Disease Control and Prevention reports infections have proven to increase patient length of stays, mortality rates and unnecessary use of antibiotics — leading to higher costs for health care institutions.